Literature DB >> 18292533

Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO.

Charles H Cook1, Alice A Bickerstaff, Jiao-Jing Wang, Tibor Nadasdy, Patricia Della Pelle, Robert B Colvin, Charles G Orosz.   

Abstract

MHC-mismatched DBA/2 renal allografts are spontaneously accepted by C57BL/6 mice by poorly understood mechanisms, but both immune regulation and graft acceptance develop without exogenous immune modulation. Previous studies have shown that this model of spontaneous renal allograft acceptance is associated with TGF-beta-dependent immune regulation, suggesting a role for T regulatory cells. The current study shows that TGF-beta immune regulation develops 30 days posttransplant, but is lost by 150 days posttransplant. Despite loss of detectable TGF-beta immune regulation, renal allografts continue to function normally for >200 days posttransplantation. Because of its recently described immunoregulatory capabilities, we studied IDO expression in this model, and found that intragraft IDO gene expression progressively increases over time, and that IDO in "regulatory" dendritic cells (RDC) may contribute to regulation associated with long-term maintenance of renal allografts. Immunohistochemistry evaluation confirms the presence of both Foxp3+ T cells and IDO+ DCs in accepted renal allografts, and localization of both cell types within accepted allografts suggests the possibility of synergistic involvement in allograft acceptance. Interestingly, at the time when RDCs become detectable in spleens of allograft acceptors, approximately 30% of these mice challenged with donor-matched skin allografts accept these skin grafts, demonstrating progression to "true" tolerance. Together, these data suggest that spontaneous renal allograft acceptance evolves through a series of transient mechanisms, beginning with TGF-beta and T regulatory cells, which together may stimulate development of more robust regulation associated with RDC and IDO.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292533      PMCID: PMC2365502          DOI: 10.4049/jimmunol.180.5.3103

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance.

Authors:  Luis Graca; Sara Thompson; Chun-Yen Lin; Elizabeth Adams; Stephen P Cobbold; Herman Waldmann
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells.

Authors:  Francesca Fallarino; Carmine Vacca; Ciriana Orabona; Maria L Belladonna; Roberta Bianchi; Brendan Marshall; Derin B Keskin; Andrew L Mellor; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Int Immunol       Date:  2002-01       Impact factor: 4.823

3.  Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes.

Authors:  Angela M Alexander; Megan Crawford; Suzanne Bertera; William A Rudert; Osamu Takikawa; Paul D Robbins; Massimo Trucco
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

4.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

5.  Evidence for a limited contribution of immune regulation to cardiac allograft acceptance.

Authors:  Alice Bickerstaff; Charles Orosz
Journal:  Hum Immunol       Date:  2002-10       Impact factor: 2.850

6.  The graft helps to define the character of the alloimmune response.

Authors:  Alice A Bickerstaff; Jiao-Jing Wang; Ronald P Pelletier; Charles G Orosz
Journal:  Transpl Immunol       Date:  2002-05       Impact factor: 1.708

Review 7.  Evidence that a similar range of alloimmune responses can develop in murine and human allograft recipients.

Authors:  Charles G Orosz; Alice A Bickerstaff; Patrick Adams; Patrice Hennessey; Ronald P Pelletier
Journal:  Transpl Immunol       Date:  2002-05       Impact factor: 1.708

8.  Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens.

Authors:  Nozomu Shirasugi; Andrew B Adams; Megan M Durham; Aron E Lukacher; Huaying Xu; Phyllis Rees; Shannon R Cowan; Matthew A Williams; Thomas C Pearson; Christian P Larsen
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

9.  Identification of regulatory T cells in tolerated allografts.

Authors:  Luis Graca; Stephen P Cobbold; Herman Waldmann
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.

Authors:  Peter Terness; Thomas M Bauer; Lars Röse; Christoph Dufter; Andrea Watzlik; Helmut Simon; Gerhard Opelz
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  28 in total

Review 1.  Why some organ allografts are tolerated better than others: new insights for an old question.

Authors:  Travis D Hull; Gilles Benichou; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

Review 2.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

3.  Plasmacytoid Dendritic Cells and the Spontaneous Acceptance of Kidney Allografts.

Authors:  Mohamed B Ezzelarab; Angus W Thomson
Journal:  Transplantation       Date:  2020-01       Impact factor: 4.939

4.  An increased CD25-positive intestinal regulatory T lymphocyte population is dependent upon Cox-2 activity in the Apcmin/+ model.

Authors:  O O Faluyi; P Fitch; S E M Howie
Journal:  Clin Exp Immunol       Date:  2017-10-24       Impact factor: 4.330

Review 5.  Organ-specific differences in achieving tolerance.

Authors:  Maria Lucia L Madariaga; Daniel Kreisel; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

6.  Generation of regulatory dendritic cells after treatment with paeoniflorin.

Authors:  Dan Chen; Yingxi Li; Xiaodong Wang; Keqiu Li; Yaqing Jing; Jinghua He; Zhaoyan Qiang; Jingzhi Tong; Ke Sun; Wen Ding; Yi Kang; Guang Li
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

Review 7.  Heart transplantation: challenges facing the field.

Authors:  Makoto Tonsho; Sebastian Michel; Zain Ahmed; Alessandro Alessandrini; Joren C Madsen
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

8.  Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction.

Authors:  D Vavrincova-Yaghi; L E Deelman; H van Goor; M A Seelen; P Vavrinec; I P Kema; P Gomolcak; A Benigni; R H Henning; M Sandovici
Journal:  Gene Ther       Date:  2016-07-25       Impact factor: 5.250

9.  Donor bone marrow-derived dendritic cells prolong corneal allograft survival and promote an intragraft immunoregulatory milieu.

Authors:  Lisa O'Flynn; Oliver Treacy; Aideen E Ryan; Maurice Morcos; Marese Cregg; Jared Gerlach; Lokesh Joshi; Mikhail Nosov; Thomas Ritter
Journal:  Mol Ther       Date:  2013-07-18       Impact factor: 11.454

10.  ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms.

Authors:  Xunrong Luo; Kathryn L Pothoven; Derrick McCarthy; Mathew DeGutes; Aaron Martin; Daniel R Getts; Guliang Xia; Jie He; Xiaomin Zhang; Dixon B Kaufman; Stephen D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.